Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
STPG3 antisense RNA 1 (STPG3-AS1), also known as C9orf173-AS1 or C9orf173 antisense RNA 1, is a long non-coding antisense RNA located on human chromosome 9 (chr9:137250219-137253497, GRCh38)[1][7][10]. This gene does not encode a protein and is classified as an antisense lncRNA, typically transcribed from the opposite strand of a nearby protein-coding gene[1][10]. The current literature and genomics resources indicate no direct evidence that STPG3-AS1 functions as a therapeutic target (e.g., receptor, enzyme, transporter, etc.) or interacts with any approved drug[10]. Its precise molecular and disease roles have not been experimentally characterized; however, as with other antisense RNAs, it may be involved in regulating nearby or related gene expression through mechanisms such as transcriptional interference, chromatin modification, or RNA-mediated gene regulation[3]. There are no known drugs, biomarkers, or specific disease associations reported for STPG3-AS1 in available databases, and it is not currently recognized in clinical contexts as a target for therapy or diagnostics[10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on STPG3 antisense RNA 1 (STPG3-AS1).